<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>BioGen Research Portal – RVK-17</title>
<link rel="icon" href="favi1.png">
<meta name="viewport" content="width=device-width, initial-scale=1.0">

<style>
body {
    margin: 0;
    padding: 0;
    font-family: Verdana, sans-serif;
    background-color: #ffffff;
    color: #333;
    line-height: 1.6;
}

/* FROSTED NAVBAR (matches site) */
.navbar {
    position: fixed;
    top: 0;
    width: 100%;
    padding: 18px 6%;
    display: flex;
    justify-content: space-between;
    align-items: center;

    background: rgba(255, 255, 255, 0);
    backdrop-filter: blur(0px);
    transition: background 0.4s ease, backdrop-filter 0.4s ease,
                padding 0.4s ease, box-shadow 0.4s ease;
    z-index: 999;
}
.navbar.scrolled {
    background: rgba(255, 255, 255, 0.8);
    backdrop-filter: blur(14px);
    box-shadow: 0 4px 18px rgba(0,0,0,0.15);
    padding: 10px 6%;
}
.navbar img {
    height: 55px;
    transition: height 0.4s ease;
}
.navbar.scrolled img { height: 45px; }
.nav-links a {
    margin-left: 26px;
    font-size: 15px;
    font-weight: bold;
    color: #ffffff;
    transition: color 0.3s ease;
    position: relative;
}
.navbar.scrolled .nav-links a { color: #414445; }
.nav-links a::after {
    content: "";
    width: 0%; height: 2px;
    background-color: #312783;
    position: absolute; left: 0; bottom: -3px;
    transition: width 0.3s ease;
}
.nav-links a:hover::after { width: 100%; }

/* PAGE HEADER */
.container {
    margin-top: 150px;
    padding: 0 8%;
}
h1 {
    text-align: center;
    color: #312783;
}
.confidential {
    text-align: center;
    color: red;
    font-weight: bold;
    margin: 30px 0;
}

/* TABLE */
table {
    width: 100%;
    border-collapse: collapse;
    margin-top: 40px;
}
td {
    padding: 12px 10px;
    vertical-align: top;
}
tr:nth-child(even) {
    background-color: #f7f7f7;
}
.code {
    width: 22%;
    font-weight: bold;
    color: #312783;
}

/* FOOTER */
.footer {
    margin-top: 80px;
    background-color: #404040;
    color: white;
    padding: 40px 10%;
    text-align: center;
}
.footer a { color: #bbb; }
.footer a:hover { color: white; }
</style>

<script>
window.addEventListener("scroll", function() {
    const nav = document.querySelector(".navbar");
    if (window.scrollY > 50) nav.classList.add("scrolled");
    else nav.classList.remove("scrolled");
});
</script>
</head>

<body>

<header class="navbar">
    <img src="BiogenLogo.png" alt="Biogen Industries Logo">
    <div class="nav-links">
        <a href="index.html">Home</a>
        <a href="bgres.html">Research</a>
        <a href="bgman.html">Leadership</a>
        <a href="#">Careers</a>
        <a href="#contact">Contact</a>
    </div>
</header>

<div class="container">

    <div class="confidential">— EXTREMELY CONFIDENTIAL —</div>

    <h1>RESEARCH PRODUCT: RVK-17</h1>

    <table>
        <tr>
            <td class="code">Research Question:</td>
            <td>To determine whether the behavioural and emotional outcomes of a blood-bond analogue can be chemically induced in subjects, and to identify a practical delivery mechanism suitable for covert population-level exposure.</td>
        </tr>
        <tr>
            <td class="code">Lead Researcher:</td>
            <td>Dr Katerina Marin</td>
        </tr>
        <tr>
            <td class="code">Background:</td>
            <td>
                RVK-17 explores the development of a controllable, time-limited attachment analogue capable of producing heightened compliance, emotional alignment, and subject orientation toward a designated target individual or group.

                Two research strands were required:<br><br>
                <b>A)</b> Development of a biochemical agent capable of replicating the behavioural outcomes associated with long-term bonded conditioning.<br>
                <b>B)</b> Identification of a distribution mechanism enabling sustained, repeat dosing among both human subjects and unidentified carriers, without detection or requirement for direct administration.
            </td>
        </tr>
    </table>

    <h2 style="margin-top: 60px; text-align:center; color:#312783;">Activity Log</h2>

    <table>

        <tr>
            <td class="code">RVK-17-001 — 19/02</td>
            <td>
                Initial analogue trials. Fifty exposures administered sequentially.<br>
                Outcome: Insufficient effect. No measurable attachment behaviour.  
                Subject concluded.
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-002 — 04/03</td>
            <td>
                Reformulation produced extreme overstimulation after four exposures.  
                Rapid onset distress followed by violent self-harm response.  
                Subject terminated.  
                Notable: Reported “sweet” taste prior to behavioural collapse.
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-003 — 17/03</td>
            <td>
                Intermediate success: observable orientation and early bonding markers.  
                After nineteen exposures, subject experienced abrupt emotional destabilisation, absconded, and self-terminated before recovery possible.
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-004 — 11/04</td>
            <td>
                Stable analogue achieved. Forty-three exposures produced reliable attachment lasting approximately 30 days.  
                Notably: decay curve is gradual and less conspicuous than anticipated.  
                No attempt will be made to increase duration; current profile preferable for covert application.
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-005 — 29/04</td>
            <td>
                Supplementary trial to determine whether exposed operatives show vulnerability to feedback effects.  
                Lisinopril (5mg) co-administration prevented all measurable influence.  
                Conclusion: Identified individuals within supervising structures can be effectively immunised.
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-006 — 02/07</td>
            <td>
                Distribution Test 1: Urban vermin carriers.<br>
                Result: Exposure density insufficient for meaningful population effect. Model abandoned.
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-007 — 15/08</td>
            <td>
                Distribution Test 2: Aerosol dispersal.<br>
                Result: Unsafe volatility. Significantly hazardous to operator.  
                Discrete deployment impossible.  
                Lab technician replacement required (contact Rehema).
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-008 — 20/09</td>
            <td>
                Distribution Test 3: Human carriers.<br>
                Result: Low exposure density; insufficient repeated ingestion among target population.  
                However, RVK-17 detected in bloodstream demonstrated unexpectedly high palatability to higher-order consumers.  
                Further investigation recommended.
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-009 — 06/10</td>
            <td>
                Breakthrough.  
                Compound successfully bonded to a hybrid narcotic formulation (nicotine, benzoylmethylecgonine, metamfetamine).  
                Result: Human subjects exhibit rapid and intense dependency, enabling self-directed repeated dosing.  
                Once exposed, blood retains RVK-17 behavioural properties for 48–72 hours.  
                Withdrawal aversion ensures continued reinforcement without external intervention.
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-010 — 19/10</td>
            <td>
                Live environment pilot (n = 35).  
                Full behavioural acquisition achieved with minimal losses.  
                All subjects concluded post-trial.  
                Recommendation: scale up.
            </td>
        </tr>

        <tr>
            <td class="code">RVK-17-011 — 20/11</td>
            <td>
                Large-scale test (n = 220).  
                Acquisition: 214 subjects (97.3%).  
                Stability curve consistent with projected model.  
                Full report available: <a href="report.pdf">download here</a>.
            </td>
        </tr>
    </table>

    <div class="confidential">— EXTREMELY CONFIDENTIAL —</div>

    <!-- Encoded Tremere-flavoured hint, still plausibly meaningless to mortals -->
    <div style="text-align:center; color:#312783; font-size:13px; margin-bottom:50px;">
        aW52b2x1bnRhcnkgc3lzdGVtcyByZXF1aXJlIGNhcmVmdWwgbWFuYWdlbWVudC4gCnByZWNpc2lvbiBoYXMgYSBjb3N0
    </div>

</div>

<!-- FOOTER -->
<footer class="footer" id="contact">
    <p><strong>Contact Us</strong></p>
    <p>
        Email: <a href="mailto:biogen@techcenter.com">biogen@techcenter.com</a><br>
        16 The Edge Business Centre<br>
        Dollis Hill, London, NW2 6<br>
        United Kingdom
    </p>

    <p style="margin-top: 30px;">
        <img src="AMRC1.png" height="70">
        <img src="AMRC2.png" height="70">
    </p>

    <p style="margin-top: 20px; font-size:14px;">© 2025 BioGen Industries. All rights reserved.</p>
</footer>

</body>
</html>
